These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors. Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123 [TBL] [Abstract][Full Text] [Related]
5. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex. Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898 [TBL] [Abstract][Full Text] [Related]
7. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease. Kempf DJ Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187 [No Abstract] [Full Text] [Related]
8. Advances in automated docking applied to human immunodeficiency virus type 1 protease. Miller MD; Sheridan RP; Kearsley SK; Underwood DJ Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188 [No Abstract] [Full Text] [Related]
9. Protein promiscuity: drug resistance and native functions--HIV-1 case. Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167 [TBL] [Abstract][Full Text] [Related]
10. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478 [TBL] [Abstract][Full Text] [Related]
11. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors. Vacca JP Methods Enzymol; 1994; 241():311-34. PubMed ID: 7854186 [No Abstract] [Full Text] [Related]
12. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses. Arodola OA; Soliman ME Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167 [TBL] [Abstract][Full Text] [Related]
13. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket. Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246 [TBL] [Abstract][Full Text] [Related]
14. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies. Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742 [No Abstract] [Full Text] [Related]
15. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite. Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263 [TBL] [Abstract][Full Text] [Related]
16. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy. Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801 [TBL] [Abstract][Full Text] [Related]
17. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor. Hill R Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407 [No Abstract] [Full Text] [Related]
18. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids. Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594 [No Abstract] [Full Text] [Related]
19. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes. Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands. Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]